Mahler Jasmin, Morales-Corraliza Jose, Stolz Julia, Skodras Angelos, Radde Rebecca, Duma Carmen C, Eisele Yvonne S, Mazzella Matthew J, Wong Harrison, Klunk William E, Nilsson K Peter R, Staufenbiel Matthias, Mathews Paul M, Jucker Mathias, Wegenast-Braun Bettina M
Department of Cellular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; DZNE, German Center for Neurodegenerative Diseases, Tübingen, Germany; Graduate School for Cellular and Molecular Neuroscience, University of Tübingen, Tübingen, Germany.
Center for Dementia Research, Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA; Department of Psychiatry, New York University School of Medicine, New York, NY, USA.
Neurobiol Aging. 2015 Jul;36(7):2241-2247. doi: 10.1016/j.neurobiolaging.2015.03.011. Epub 2015 Mar 25.
Endogenous murine amyloid-β peptide (Aβ) is expressed in most Aβ precursor protein (APP) transgenic mouse models of Alzheimer's disease but its contribution to β-amyloidosis remains unclear. We demonstrate ∼ 35% increased cerebral Aβ load in APP23 transgenic mice compared with age-matched APP23 mice on an App-null background. No such difference was found for the much faster Aβ-depositing APPPS1 transgenic mouse model between animals with or without the murine App gene. Nevertheless, both APP23 and APPPS1 mice codeposited murine Aβ, and immunoelectron microscopy revealed a tight association of murine Aβ with human Aβ fibrils. Deposition of murine Aβ was considerably less efficient compared with the deposition of human Aβ indicating a lower amyloidogenic potential of murine Aβ in vivo. The amyloid dyes Pittsburgh Compound-B and pentamer formyl thiophene acetic acid did not differentiate between amyloid deposits consisting of human Aβ and deposits of mixed human-murine Aβ. Our data demonstrate a differential effect of murine Aβ on human Aβ deposition in different APP transgenic mice. The mechanistically complex interaction of human and mouse Aβ may affect pathogenesis of the models and should be considered when models are used for translational preclinical studies.
内源性小鼠淀粉样β肽(Aβ)在大多数阿尔茨海默病的Aβ前体蛋白(APP)转基因小鼠模型中表达,但其对β淀粉样变性的作用仍不清楚。我们证明,与年龄匹配的App基因缺失背景下的APP23小鼠相比,APP23转基因小鼠的脑Aβ负荷增加了约35%。在Aβ沉积速度快得多的APPPS1转基因小鼠模型中,有或没有小鼠App基因的动物之间未发现这种差异。然而,APP23和APPPS1小鼠都共同沉积了小鼠Aβ,免疫电子显微镜显示小鼠Aβ与人Aβ纤维紧密相关。与人类Aβ的沉积相比,小鼠Aβ的沉积效率要低得多,这表明小鼠Aβ在体内的淀粉样生成潜力较低。淀粉样染料匹兹堡化合物-B和五聚体甲酰噻吩乙酸不能区分由人类Aβ组成的淀粉样沉积物和人类-小鼠混合Aβ的沉积物。我们的数据证明了小鼠Aβ对不同APP转基因小鼠中人类Aβ沉积的不同影响。人类和小鼠Aβ在机制上复杂的相互作用可能会影响模型的发病机制,在将模型用于转化临床前研究时应予以考虑。